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Abstract
Background: Treatment-related outcomes in patients with extensively drug-resistant tuberculosis (XDR-TB) are poor.
However, data about the type, frequency and severity of presumed drug-associated adverse events (AEs) and their
association with treatment-related outcomes in patients with XDR-TB are scarce.
Methods: Case records of 115 South-African XDR-TB patients were retrospectively reviewed by a trained researcher. AEs
were estimated and graded according to severity [grade 0 = none; grade 1–2 =mild to moderate; and grade 3–5 = severe
(drug stopped, life-threatening or death)].
Findings: 161 AEs were experienced by 67/115(58%) patients: 23/67(34%) required modification of treatment, the
offending drug was discontinued in 19/67(28%), reactions were life-threatening in 2/67(3.0%), and 6/67(9.0%) died.,50% of
the patients were still on treatment at the time of data capture. Sputum culture-conversion was less likely in those with
severe (grade 3–5) vs. grade 0–2 AEs [2/27(7%) vs. 24/88(27%); p = 0.02]. The type, frequency and severity of AEs was similar
in HIV-infected and uninfected patients. Capreomycin, which was empirically administered in most cases, was withdrawn in
14/104(14%) patients, implicated in (14/34) 41% of the total drug withdrawals, and was associated with all 6 deaths in the
severe AE group (renal failure in five patients and hypokalemia in one patient).
Conclusion: Drug-associated AEs occur commonly with XDR-TB treatment, are often severe, frequently interrupt therapy,
and negatively impact on culture conversion outcomes. These preliminary data inform on the need for standardised
strategies (including pre-treatment counselling, early detection, monitoring, and follow-up) and less toxic drugs to optimally
manage patients with XDR-TB.
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Introduction
Over the last two decades the entity of multidrug resistant
tuberculosis (MDR-TB i.e. resistance to at least isoniazid and
rifampicin) has emerged. In 2008 there were approximately 440
000 cases of MDR-TB globally[1]. Between 5 to 10% of MDR-TB
cases are thought to be due to extensively drug resistant
tuberculosis (XDR-TB i.e. resistance to rifampicin, isoniazid,
any fluoroquinolone and one of the 2nd line injectable agents i.e.
kanamycin, amikacin or capreomycin). MDR-TB and XDR-TB
now threaten to destabilise TB control in several regions of the
world including Africa, Eastern Europe, Russia, central Asia, India
and China[2].
In high burden settings treatment outcomes of MDR-TB are
disappointing with only ,50% of patients successfully completing
treatment[3]. Outcomes in XDR-TB are poorer. We and others
have recently shown that, in contrast to low and intermediate
burden settings[4], less that 20% of patients with XDR-TB
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culture-convert in high burden settings[5,6]. Treatment options,
because of the high grade of drug resistance are severely limited
and the higher the total number of appropriate drugs used in a
regimen the better the outcome[5]. Thus, treatment interruption
due to any cause may potentially subvert successful outcome in
patients with XDR-TB. Failure to identify and manage presumed
drug-associated adverse events (AEs) may also have serious
implications for patient perceptions about toxicity versus benefit,
and thus may impact on compliance. Even in adherent inpatients,
we and others have recently shown that AEs are common in
patients with XDR-TB[5], [7].
However, data about the relationship between AEs and
treatment-related outcomes in patients with drug-resistant TB
are scarce. It is also unclear how the M. tuberculosis strain
phenotype and host factors such as HIV co-infection impact on
the frequency and severity of AEs, and associated clinical
outcomes. Given that capreomycin modulates outcomes and is a
vital backbone of most XDR-TB treatment regimens[6], the
frequency of AEs to capreomycin and their temporal relationship
to treatment initiation are of interest. Collectively, these data can
inform on several aspects of management including the design and
monitoring of treatment regimens for XDR-TB and formulating
strategies to prevent treatment interruption, thus facilitating
compliance and minimising treatment failure. To address these
gaps in our knowledge and, in particular, to evaluate the
association of AEs with outcomes we reviewed the case records
of 115 patients treated for XDR-TB at three treatment centres in
South Africa.
Methods
Study setting and participants
We retrospectively reviewed the case records of 115 consecutive
laboratory-confirmed XDR-TB patients diagnosed between Au-
gust 2002 and February 2008 at three designated XDR-TB
treatment centres in South Africa (see Figure 1 for the study
outline). Patients were admitted to the facilities for the duration of
their treatment and thus adherence was assumed to be excellent
unless the patients self discharged (designated as default from
treatment). Case records were comprehensively reviewed by a
trained researcher for AEs listed in Table 1 (including duration,
type and severity), drug regimen used (dose, indication, route of
administration), culture conversion and mortality outcomes, and
HIV status. Associated demographic and clinical information were
also transcribed into a case record form, and the information
captured by double data entry.
Ethics
Ethical approval was provided by the UCT Research Ethics
Committee. As per the regulations at UCT patient-provided
written informed consent was not required as retrospective
annonymised data was used in this study.
Diagnosis and treatment regimens
The standard definition of XDR-TB was used to define patient
inclusion[8]. Drug-susceptibility testing to capreomycin, terizi-
done/cycloserine and fluoroquinolones other than ofloxacin was
unavailable as these tests are not undertaken by the National
Treatment Program (NTP). The drugs used in the treatment
regimens are shown in Table 2. XDR-TB treatment was only
initiated and administered in hospital with the use of capreomycin
and para-aminosalycilic acid (PAS) as the anchor drugs since late
2006/early 2007. Treatment with capreomycin was empiric and
in almost all cases was given in the absence of prior susceptibility
testing. Third-line drugs (clarithromycin, dapsone, amoxicillin/
clavulanate and azithromycin) were used at the discretion of the
attending clinician. High-dose INH was administered at a dose of
10 mg/kg. Clofazimine and moxifloxacin was used in selected
centres on a limited basis. ART was offered to all HIV co-infected
patients irrespective of the patients’ CD4 count.
Definition of adverse drug reactions
For the purposes of analysis grades 1 and 2 AEs were considered
mild to moderate, and grade 3–5 severe (see definitions in Table 1).
Events where the drug was discontinued was designated grade 3.
Multiple events of the same AE were counted separately.
Outcomes
All cause mortality and culture conversion were the primary
outcomes of interest. Conversion was judged to have occurred
when two consecutively negative cultures were obtained, 1 month
apart, and providing that a culture taken at initiation of XDR-TB
treatment was positive. Time to conversion was measured in days
from treatment start date to the take date of the first of the two
negative cultures.
Mycobacterium tuberculosis strain typing
A subset of 53 XDR-TB isolates from patients from the Western
Cape were genotyped by IS6110 DNA fingerprinting [9] and
spoligotyping [10]. Strains were categorised as Beijing or non-
Beijing according the their spoligotype signature [11].
Data handling and statistical analysis
A data risk management tool, including double data entry, was
used to ensure data integrity. Categorical data were compared
using x2 test and continuous data were compared using Mann-
Whitney test or Kruskal-Wallis test (SPSS, Version 17). Cox
proportional hazards regression models were fitted to determine
risk factors associated with outcomes in a time-to-event (conver-
sion and mortality) based analysis. These factors included AEs,
previous MDR-TB, 6 month culture conversion (when assessing
risk factors for death), HIV status, usage of ART, weight, age, sex,
ethnicity, number of previous TB episodes, number of drugs used
in a regimen. Factors found to be significant in univariate were
included in the final multivariate analysis. Kaplan-Meier’s method
was used to calculate probabilities of events, and the Log-rank test
was used to compare these probabilities by group. All tests were
two-sided, and a p-value ,0.05 was considered significant. The
proportionality assumption of the Cox models was tested using –
ln[–ln (survival)] curves and regression of scaled Schoenfeld
residuals on functions of time.
Results
Demographic and clinical characteristics
AEs were reported in 58.3% (67/115) of patients. The
breakdown by severity of AE and HIV status, stratified by number
of patients and total number of AEs, is shown in Figure 1. The
median CD4 count in HIV-infected persons was 204 (range 13–
893) cells/mm3. We could not identify any demographic and
clinical variables that were specifically associated with the
development of AEs (grade 1 to 5) compared to those who did
not develop an AE (grade 0). However, patients with severe AEs
(grade 3 to 5), when compared to those with mild, moderate or no
AEs (grade 0, 1 and 2), were more likely to be female, have had
previous MDR-TB or drug sensitive TB, and had fewer drugs in
their treatment regimens (Table 3). Furthermore, in the multivar-
iate analysis only a history of previous MDR-TB was indepen-
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dently associated with the likelihood of developing severe AEs
(grade 3 to 5); p = 0.009. The overall median (IQR) duration of
follow-up (months) within the cohort was 7.3 (3.1–12.6). As at the
study censure date 21% of patients had died, 22% had defaulted
treatment, 7% were cured or had completed treatment, and the
remaining of 50% were on on-going treatment.
Frequency and severity of AEs
161 AEs were experienced by 67/115 (58%) patients (Figure 1;
upper panel). When the results were stratified by the number of
patients 17/67 (25.4%) patients required no intervention (grade 1);
23/67 (34.3%) required modification of treatment (grade 2), the
offending drug was discontinued in 19/67 (28.3%) of patients
(grade 3); reactions were life-threatening in 2/67(3.0%; grade 4),
and 6/67(9.0%) died (grade 5). When the results were analysed by
the number of AEs (Figure 1; lower panel): in 58/161 (36%)
Figure 1. Study plan stratified according to treatment site, HIV status and severity of adverse drug reactions.
doi:10.1371/journal.pone.0063057.g001
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instances an AE was described but there was no intervention; 69/
161 (43%) required modification of treatment in either the dose or
frequency of the drug being taken, or, the prescription of an
additional drug to treat the AE; the offending drug was withdrawn
in 34/161 (21%); the AE was life-threatening in 2/161 (1.2%)
instances (both AEs were due to renal failure), and death was
associated with 6/161 (4%) of AEs. All 6 deaths were associated with
capreomycin (hypokalaemia in 1 patient and renal failure in 5
others), and these patients died at a median of 14 days (range of 9–
73 days) after starting therapy including Capreomycin. The severity
of AEs was not associated with the frequency and duration with
which the drug was used, or the resistance pattern of the drug.
Culture conversion and mortality outcomes stratified by
HIV status
Culture conversion occurred in 26/115 (22.6%) of patients.
Patients with grade 3–5 AEs had a lower sputum culture
conversion rate compared with those with grade 0–2 AEs [2/27
(7.4%) vs. 24/88 (27.3%); p = 0.02; Figure 2A]. In a Cox
regression of the whole cohort the hazard ratio for AE (grade 3–
5 AEs compared with grade 0–2 AEs) as a risk factor for culture
conversion was 0.22 (0.05–0.95); p = 0.04. There were no other
significant variables associated with culture conversion.
In contrast to HIV-uninfected patients (Figure 2C), HIV-
infected patients (Figure 2B) with severe AEs (grade 3–5) had a
significantly lower sputum culture conversion rate than those with
grade 0–2 AEs [0/15 (0%) vs. 10/33 (30.3%), p = 0.02].
Of the 115 patients in the cohort, 30 (26.1%) died. Patients with
grade 3–5 AEs had a higher death rate compared with those with
grade 0–2 AEs [13/27 (48.1%) vs. 17/88 (19.3%); p = 0.003;
Figure 2D]. However, in a multivariate Cox regression model for
risk factors for death in the whole cohort, only culture non-
conversion and previous MDR-TB, but not adverse events, were
independently associated with death (Table 4).
In HIV-infected patients mortality rates were higher in those
with grade 3–5 (severe) AEs compared to those with grade 0–
2 AEs [7/15 (46.7%) vs. 8/33 (24.2%); p= 0.12; Figure 2D, 2E,
2F]. Similarly, in the HIV-uninfected patients, those with severe
AEs had a higher death rate compared to those without severe
AEs [6/12 (50.0%) vs. 9/55 (16.4%); p = 0.02; Figure 2F]. Of the
13 all-cause deaths occurring in the severe AE group, 6 were due
to an AE itself (5 due to renal failure and 1 due to hypokalaemia-
all likely ascribable to capreomycin). These patients were not
Table 1. Definitions used to grade, identify and classify adverse events.
A. Grading of adverse events1
grade 0 no AE
grade 1 mild AE i.e. described in the patient’s management records but no action was taken
grade 2 moderate AE resulting in either changing the dose or frequency of the offending drug or another
drug(s) was added to manage the AE
grade 3 the side effect was severe enough for the offending drug to be stopped
grade 4 the AE was life threatening or disabling
grade 5 the AE caused the death of the patient
B. Definitions used to identify and classify adverse events.
Nausea, vomiting, diarrhoea. Other GI symptoms: abdominal pain,
dyspepsia, and epigastric discomfort
As documented by the physician or nursing staff
Dizziness/disorientation/confusion
Body aches/pains/cramps
Headache
Sore tongue/throat
Generalised itchiness
Fatigue
Numbness of extremities Symptoms and findings consistent with neuropathy, e.g. pain or numbness of the distal extremities
diagnosed by a physician.
Skin reaction A dermatological reaction felt to be related to anti-tuberculosis medications as documented by the
physician or dermatologist
Hypokalaemia ,3.5 meq/L (normal range: 3.5–5.5 meq/L)
Hypothyroidism At least one thyroid stimulating hormone (TSH) result .4.94 IU/ml (normal 0.35–4.94) that was
thought to be unrelated to the sick euthyroid syndrome
Depression/psychosis As diagnosed by the TB physician and/or psychiatrist, based on international classification of
diseases (ICD)-10 criteria
Visual disturbance Diagnosed by the physician/eye specialist as being related to the TB drugs
Arthralgia Painful joints as reported by patient and documented by physician or nurse
Ototoxicity Hearing loss confirmed by audiometry and/or physical examination
Renal impairment/renal failure Creatinine .100 mmol/L
Hepatotoxicity Raised bilirubin or elevated transaminases .3 times the upper limit of normal, and ascribable to a
specific drug
1These were graded according to the modified American National Institute of Health common terminology criteria for adverse events [CTCAE].
doi:10.1371/journal.pone.0063057.t001
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terminally or critically ill and there was a clear temporal relationship
between the initiation of the drug and the patient’s death. Five out of
the 6 patients who died from AEs were HIV-infected.
25/115 (21.7%) of patients defaulted (self discharged) from the
inpatient facilities. There was no difference between the propor-
tion of patients with severe AEs among defaulters and the
proportion with severe AEs among non-defaulters [7/25 (28%) vs.
27/90 (30%); p = 0.96].
AEs by HIV status
In HIV-infected versus uninfected persons there was no
significant difference between the proportion of persons with AEs
[29/48 (60.4%) vs. 38/67 (56.7%); p= 0.26)], the number of total
AEs per person [2.37 vs. 2.42 AEs per person; p= 0.15], and the
number of severe AEs [20/69(29.0%) vs. 14/92(15.2%); p= 0.31].
Thus, the type, frequency and severity of the number of AEs was
similar in HIV-infected and uninfected patients. However, those
who died of an AE were more likely to be HIV-infected than HIV
un-infected [5/6 (83.3%) vs. 1/6 (16.7%), p= 0.01)].
34/48 (71%) HIV-infected patients were on ART (active anti-
retroviral therapy). 23/34 (68%) of patients were on a combination
of lamivudine (3TC), stavudine (D4T) and efavirenz (EFV). In
HIV-infected patients the number of patients experiencing an AE
was not significantly different in those taking ART vs. those not
taking ART [29/34 (85.3%) vs. 8/14 (57.1%); p = 0.71]. Similarly,
the frequency of severe AEs was not significantly different in the
same groups [11/34 (32.3%) vs.6/14 (43.0%)]. Thus, ART did not
impact on the frequency of AEs and was generally well tolerated.
The role of overlapping toxicities between ART and anti-TB
drugs could not specifically be evaluated but the number of
patients experiencing an AE was significantly higher in those
taking ART compared to HIV un-infected patients [29/34
(85.3%) vs. 38/67 (56.7%); p = 0.008]. Nevertheless, the propor-
tion of patients experiencing a severe AE was not significantly
different in those taking ART compared to HIV un-infected
patients [11/34 (32.3%) vs. 12/67 (17.9%); p = 0.17].
Table 2. Specific drugs, the dosages used in XDR-TB treatment regimens, and the frequency of drug withdrawal due to adverse
events relative to the number of patients prescribed the drug.
Drug dosages used
No. of patients who
received a drug as
part of the XDR-TB
regimen n=115(%)
Number of patients in
whom the drug was
withdrawn relative to
the total number
receiving the drug (%)
Proportion of
severe AE
[total = 34] due to a
specific drug (%)
Isoniazid 4–6 mg/kg/daily 39/115(34) -
Ethambutol 25 mg/kg/daily 46/115 (40) 1/46(2.2) 1/34(2.9)
Pyrazinamide 30–40 mg/kg/daily 80/115(69.6) - -
Amikacin 15–20 mg/kg/daily* 3/115(2.6) 1/3 (33.3) 1/34(2.9)
Kanamycin 15–20 mg/kg/daily* 4/115(3.5) - -
Ofloxacin 600–800 mg daily 29/115(25.2) - -
Moxifloxacin 400 mg daily 2/115(1.7) - -
Ethionamide 15–20 mg/kg/daily 66/115(57.3) 7/66(10.6) 7/34(20.6)
Capreomycin 15–20 mg/kg/daily* 104/115(90.4) 14/104 (13.5) 14/34(41.2)
Para-aminosalicylic acid 8 g (400 mg BD) 101/115(87.8) 7/101(6.9) 7/34(20.5)
Terizidone/Cycloserine 500–750 mg daily 104/115(90.4) 2/104(1.9) 2/34(5.9)
Clarithromycin 1 g (500 mg BD) 77/115(66.9) - -
Amoxicillin-clavulanate 375 mg 65/115(56.5) 2/65(3.1) 2/34(5.9)
Clofazimine 200 mg (100 mg BD) 28/115(24.3) - -
Dapsone 100–200 mg daily 36/115(31.3) - -
Azithromycin 500 mg 3xweekly 11/115(9.6) - -
INAT (INH+thiacetazone) 3 tabs daily 2/115(1.7) - -
Rifabutin 300 mg daily 1/115(0.87) - -
Type of ART Dosage used Number of XDR-TB
patients receiving drug
Number of HIV-infected
persons receiving ART
n=115 (%) n=34 (%)
3TC (Lamivudine) 80 mg (40 mg BD) 29/115 (25) 29/34 (85.3) -
D4T (Stavudine) 300 mg (150 mg BD) 25/115 (22) 25/34 (73.5) -
EFV (Efavirenz) 600 mg nocte 25/115 (22) 25/34 (73.5) -
NVP (Nevirapine) 200 mg BD 4/115 (3) 4/34 (11.8) -
AZT (Zidovudine) 600 mg (300 mg BD) 5/115 (4) 5/34 (14.7) -
Lopinavir/Ritonavir 800 mg (400 mg BD) 1/115 (1) 1/34 (2.9) -
*(Maximum dose, 1 g) 5 days/week.
doi:10.1371/journal.pone.0063057.t002
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Type of adverse events and drug withdrawal
Of all drug discontinuations, (n = 34), capreomycin (Capstat;
Pharmacare Johannesburg) was the drug withdrawn most often in
14/34 (44.1%) of cases, followed by PAS in 7/34 (20.5%), and
ethionamide in 7/34 (20.6%) (Table 2). The withdrawal of
capreomycin due to an AE occurred at a median of 73 days (range
9–485) days after initiation of therapy. Persons who took
capreomycin and had AEs, compared to those that took
capreomycin but had no AEs, were more likely to be taking
concurrent ethambutol, augmentin, ethionamide and PZA
(p,0.05).
The breakdown of AEs by cause is shown in Table 5. Overall,
nausea and vomiting (22%), diarrhoea (14%), and other GI
symptoms (14%) were the commonest causes of AEs and their
frequency did not differ significantly by HIV status. The most
common cause of grade 0–2 AEs (79% of the total number of AEs)
were GI symptoms overall (nausea, vomiting, diarrhoea and
others), which caused ,50% of AEs in this severity category. The
most common causes of grade 3–5 AEs (21% of the total number
of AEs) were specifically vomiting (29% of severe AEs) and renal
failure (21%).
Some patients experienced multiple AEs. These were frequently
clustered in the gastro-intestinal subgroup. Thus, of those who had
diarrhoea 15/22 (68.2%) also experienced nausea and vomiting,
and 10/22 (45%) nausea and vomiting together with abdominal
pain and dyspepsia. AE clustering was also evident in the
neurological category (overlapping symptoms of headaches,
dizziness, generalised aches and pains etc.).
For the 18 drugs used in the XDR-TB treatment regimens, the
severity of AEs was not related to the number of patients who
received each drug, total duration of treatment (months), or the
proportion of resistant isolates.
AEs stratified by Mycobacterium tuberculosis strain type
Of the 115 patients with XDR-TB, isolates were available for
genotyping in 53 of the patients from the Western Cape.
Significantly more patients had a Beijing compared to a non-
Beijing strain [43(81%) vs. 10 (1%); p= 0.0001]. The severity of
AEs was not significantly different in the Beijing and non-Beijing
families (Table 6).
Table 3. Socio-demographic and treatment related clinical characteristics of 115 patients who initiated treatment for extensively
drug-resistant tuberculosis (XDR-TB).
Grade: 0–2 (none/mild/moderate) adverse
events
Grade 3–5 (severe/life threatening/
death) adverse events P value
n=88 (% unless otherwise stated) n=27 (% unless otherwise stated)
Sex
male 53(60.2) 9(33.3) 0.014
Ethnicity
mixed origin 46(52.3) 14(51.9) 0.969
HIV status
infected 33(37.5) 15(55.6) 0.096
ART
yes 23(71.8) 11(73.3) 0.917
Number of previous sensitive TB episodes
(IQR)
1(1–2) 1(1–2) 0.033
Previous MDR-TB episodes
yes 47(53.4) 22(81.5) 0.009
Previous MDR-TB episodes (IQR) 1(1–1) 1(1–2) 0.467
Number of drugs in the treatment regimens
(IQR)
6(5–7) 5(4–6) 0.001
Smoking
current 37(42) 12(44.4) 0.454
non 36(40.9) 13(48.1)
previously 15(17) 2(7.4)
Weight at diagnosis of XDR-TB (IQR) 48(44–59) 48(36–59) 0.626
Age at diagnosis of XDR-TB (range in years) 31.0(26.4–42.0) 36.8(25.0–46.2) 0.892
Outcome-related variables
Died
yes 17(19.3%) 13(48.1%) 0.003
Conversion
yes 24(27.3%) 2(7.4%) 0.035
*The only other ethnic group in the cohort was Black. Grade 0–2 AE 42(47.7%). Grade 3–5 13(48.1%).
doi:10.1371/journal.pone.0063057.t003
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Discussion
This is the first comprehensive report of AEs and their
association with outcomes in a large cohort of patients with
XDR-TB. Our key findings were that: (i) the frequency of AEs
with XDR-TB treatment regimens is high (,60%), and in ,40%
of patients the AE was associated with interruption of therapy, life-
Figure 2. Kaplan-Meier probabilities of XDR-TB culture-conversion in: (A) The whole cohort of patients who experienced AEs
stratified by severity score i.e. none or mild to moderate (grade 0, 1 and 2; dashed line) versus severe (grade 3 to 5; solid line); (B)
HIV-infected patients whom experienced AEs stratified by stratified by severity score; (C) HIV-uninfected patients who experienced
AEs stratified by stratified by severity score, and Kaplan-Meier probabilities of death: (D) The whole cohort of patients from the
date of treatment-initiation, (E) HIV-infected patients who experienced AEs stratified by severity score, and (F) HIV-uninfected
patients who experienced AEs stratified by severity categories.
doi:10.1371/journal.pone.0063057.g002
Table 4. Univariate and multivariate analysis of factors associated with mortality in 115 patients with XDR-TB.
Factor Univariate analysis Multivariate analysis
Hazard Ratio (95%CI) P-value Hazard Ratio (95%CI) P-value
Adverse event
Grade 3–5 2.39(1.14–4.97) 0.02 1.43(0.67–3.05) 0.35
Grade 0–2 1 1
Previous MDR TB
Yes 3.27(1.32–8.03) 0.01 2.91(1.16–7.35) 0.02
No 1 1
6 month Culture conversion
Yes 0.09(0.01–0.63) 0.02 0.10(0.01–0.747) 0.03
No 1 1
doi:10.1371/journal.pone.0063057.t004
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threatening reactions, or fatal consequences; (ii) those who died of
an AE were more likely to be HIV-infected and thus greater
vigilance is required in this group; (iii) those with severe AEs have
poorer culture conversion but not higher mortality underscoring
the need for careful treatment monitoring for early detection of
AEs, and (iv) capreomycin was likely the most common cause of
drug withdrawal (44% of all withdrawals), was likely responsible
for over 40% of severe AEs and all AE-related deaths, and thus
careful monitoring of this drug is mandatory.
A fundamental finding of this study is that XDR-TB patients
with severe AEs had poorer culture-conversion outcomes. By
contrast, in patients with MDR-TB from Turkey[12] and Russia
where AEs were common (,70% of patients) AEs were not
associated with unfavourable outcomes[13]. Thus, in contrast to
MDR-TB, in XDR-TB patients the consequences of AE-
associated interruption of individual drugs impacts on culture-
conversion outcomes. This most likely reflects discontinuation of
crucial drugs like capreomycin. Thus, interruption of drug therapy
has deleterious consequences. In keeping with the findings of
O’Donnell et al [7] we found no association between AEs and
mortality in the multivariate analysis.
In our study persons who took capreomycin and had AEs,
compared to those that took capreomycin but had no AEs, were
more likely to be taking concurrent ethambutol, augmentin,
ethionamide and PZA, raising the possibility that capreomycin
withdrawal in some cases may have been unwarranted. However,
these confounding drugs are rarely a cause of renal failure and are
Table 5. Type of adverse event that occurred (n = 161) and total number of patients experiencing these adverse events (n = 115) in
patients from the Western Cape, Northern Cape and Gauteng provinces who initiated treatment for XDR-TB.
Presumed drug-associated adverse event Number of AEs stratified by HIV status (n=161)
Number of patients with AEs stratified by HIV
status (n =115)
n (%) n (%)
HIV+(69) HIV- (92) Total AE (161) HIV+(48) HIV- (67) Total patients
(115)
Nausea and/or vomiting 15(9) 20(12) 35 (22) 15(31) 20(30) 35(30)
Diarrhoea 8(5) 14(9) 22 (14) 8(17) 14(21) 22(19)
Other GI symptoms: abdominal pain, dyspepsia,
epigastric discomfort, cramps
6 (4) 16(10) 22 (14) 6(13) 16(24) 22(19)
Dizziness/disorientation 4(2) 9(6) 13 (8) 4(8) 9(13) 13(11)
Hearing loss 2(1) 8(5) 10 (6) 2(4) 8(12) 10(9)
Renal failure 4(2) 3(2) 7 (4) 4(8) 3(4) 7(6)
Body aches/cramps 5(3) 5(3) 10 (6) 5(10) 5(7) 10(9)
Headache 6(4) 2(1) 8 (5) 6(13) 2(3) 8(7)
Skin reaction 3(2) 4(2) 7 (4) 3(6) 4(6) 7(6)
Hypokalaemia 5(3) 2(1) 7 (4) 5(10) 2(3) 7(6)
Hypothyroidism 3(2) 3(2) 6 (4) 3(6) 3(4) 6(5)
Depression 1(1) 1(1) 2 (1) 1(2) 1(1) 2(2)
Sore tongue/throat 1(1) 1(1) 2 (1) 1(2) 1(1) 2(2)
Numbness of extremities 2(1) 0 2 (1) 2(4) 0 2(2)
Generalised itchiness 1(1) 1(1) 2 (1) 1(2) 1(1) 2(2)
Psychosis 0 1(1) 1(1) 0 1(1) 1(1)
Renal impairment 1(1) 0 1(1) 1(2) 0 1(1)
Fatigue 0 1(1) 1(1) 0 1(1) 1(1)
Visual disturbance 1(1) 0 1(1) 1(2) 0 1(1)
Thrombophlebitis 0 1 (1) 1(1) 0 1(1) 1(1)
Arthralgia 1(1) 0 1(1) 1(2) 0 1(1)
Total # AE stratified by HIV Status 69(43 92(57) 161(100)
doi:10.1371/journal.pone.0063057.t005
Table 6. Effect of TB strain type on AEs stratified by Beijing
and non-Beijing strain type.
Strain type Beijing Non-Beijing
n(%) n (%)
Severity of AE AEs 0–2 AEs 3–5 AEs 0–2 AEs 3–5
HIV-infected 9/14 5/14 1/3 2/3
(64.3) (35.7) (33.3) (66.7%)
HIV-uninfected 20/29 9/29 5/7 2/7
(69.0) (31.0) (71.4) (28.6)
Sub-totals 29/43 14/43 6/10 4/10
(67.4)* (32.6)* (60) (40)
Total 43/53(81)** 10/53(19)**
*p = 0.03 (severe vs. mild to moderate AEs).
**p = 0.0001 (total Beijing versus non-Beijing).
doi:10.1371/journal.pone.0063057.t006
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not associated with hypokalemia. The high capreomycin toxicity
seen in our study (almost half of all drug withdrawals due to an
AE) is in keeping with the findings of a Peruvian study where 31%
of 115 MDR-TB patients had hypokalaemia, which was indepen-
dently associated with the administration of capreomycin[14].
Based on our findings we suggest weekly checks of renal function
and electrolytes in the 1st 4 weeks of therapy, and then every 2
weeks for the next two months, and monthly thereafter. Our data
also raises the question of routine supplementation of electrolytes
in patients on capreomycin treatment, and capreomycin drug
susceptibility testing in all patients with suspected or proven XDR-
TB. We suggest active monitoring for AEs, correct dosing by body
weight, correction of dehydration, and regular monitoring of renal
function and electrolytes, particularly in those with risk factors
(hypertension, diabetes, HIV-associated nephropathy, vomiting
and diarrhoea, dehydration, electrolyte abnormalities, diuretic
usage, alcohol abuse, and use of potentially nephrotoxic drugs
such as tenofovir, cotrimoxazole). This has implications for the
out-patient management of XDR-TB, which is currently being
rolled out in high burden settings due to the sheer burden of cases
that have overwhelmed designated facilities[4]. Our data inform
on resource allocation by national TB programmes in high burden
settings that will need to take into account provision of monitoring
and laboratory infrastructure when planning decentralised and
nurse-led services for drug-resistant TB. Given the associated
poorer outcomes in XDR-TB patients with AEs, health care
workers should be educated about the recognition, management,
as well as appropriate referral pathways of those experiencing AEs,
and patients should be followed up more closely and offered
appropriate counselling to ensure drug adherence. Our recom-
mendations are easily implementable and do not detract from
providing decentralised MDR treatment services in resource-poor
settings.
Nausea and vomiting, in keeping with the findings of Shin et
al.[13], was the most common reason for discontinuation of drug
therapy (in any severity category) and needs to be managed with
patient counselling, anti-emetics, and/or splitting of the dose to
improve tolerability. AEs although frequent were not more
common in HIV-infected patients unlike observations that
we[15] and others[16] have documented in patients with drug-
sensitive TB. The reasons for this are unclear but could reflect
poorer absorption of second line drugs and hence lower serum
levels, or, be an ascertainment bias as HIV-infected patients may
have died prior to diagnosis. Nevertheless, HIV-infected patients
were more likely to die from severe AEs and increased vigilance
and correct dosing by body weight is required in this group.
The frequency of AEs in this study (,60%) are similar to those
that evaluated AEs to second line drugs in the context of XDR-TB
(58%)[7] and MDR-TB (73.3% in Tomsk, Russia[13] and 69,2%
in Istanbul Turkey[12]) but twice that of AEs to first line drugs in
those with drug-sensitive TB[17]. Suspension of any agent (28% in
our study) occurred at a similar frequently compared to a large
multi-centric study in patients with MDR-TB (30%)[18] and in
patients with XDR-TB[7], more frequently in a Peruvian study in
patients with MDR-TB (14%) [19], but less frequently than in
Turkish patients with MDR-TB (55%)[12]. This may reflect the
heterogeneity of several factors including HIV rates, previous
history of TB of any type, resistance profiles, drug regimens,
physician management and ascertainment bias.
We found no significant association between strain genotype
and the frequency or severity of AEs. This may reflect a true lack
of association or type 2 error given the small numbers of isolates
that were accessible for genotyping. Association with strain type is
of interest because Beijing strains are thought to be more virulent
(more cavitation and greater disease extent) and such patients may
require a prolonged injectable phase and an increased number of
drugs in a regimen. Moreover, recent data suggest that DR-TB
strains have, in addition to resistance conferring mutations,
hundreds of compensatory mutations that may alter the structure
and hence antigenic properties of the organism[20]. This may
impact host immune profiles and hence interaction with drug
compounds. Further and larger studies are required to clarify this
issue.
Similar to findings in earlier studies in drug-sensitive
TB[16,17,21], a higher number of women experienced AEs.
The reason for this remains unclear. Similar to the findings in the
context of drug-sensitive TB[21], the higher rate of AEs in those
with prior MDR-TB may reflect prior sensitisation, higher drug
levels in patients with a lower body weight, and the generally
poorer health status in keeping with chronic disease.
There are several limitations of our study. These include the
retrospective study design, lack of complete adherence data,
ascertainment bias due to retrospective data capture from medical
notes, physician bias, use of a single researcher to capture data on
a standardised template, inability to calculate drug-specific AE
rates and AE rates per person months of exposure, or to
definitively delineate AEs from disease-related morbidity in
HIV-infected patients. However, this is difficult to calculate even
in prospective studies because of the inability to ascribe a
particular AE to a specific drug in a multidrug regimen. Thus,
we chose the term adverse event (rather than adverse drug
reaction) as in some cases it was impossible to ascribe the event to
a drug rather than HIV, and in other instances it was impossible to
determine whether it was TB drug or ARV-related, and in each of
these cases which specific drug was implicated. Nevertheless, the
patients were consistently seen by a small group of experienced
clinicians who based assessments on their clinical judgement and
temporal relationship to symptoms, signs, and laboratory data,
and we only extracted variables that could be confidently
ascertained. We were also reliant on the judgement and
investigative evaluation of clinicians who ascribed renal failure to
capreomycin rather than dehydration, vomiting and diarrhoea
etc., and we could only captured events ascribed by a clinician to
be significant. Thus, our analysis may reflect this clinical bias.
Given that DST for capreomycin was unavailable, we may have in
many, or possibly the majority of cases, inappropriately treated
with capreomycin and hence over-estimated the magnitude of AE.
However, DST for capreomycin is unreliable and clinical benefit
may still occur, even in the face in-vitro resistance, and cross-
resistance between capreomycin and amikacin is greater than for
kanamycin, which is used in our treatment programme. A further
limitation is that although all the patients were hospitalised and
drugs administered strictly on a DOT basis, it remains unclear to
what extent patients may have circumvented this process, and this
could have confounded our findings. Furthermore, we did not
capture the pill burden or its relationship to the frequency and
severity of adverse events. Survivor selection bias may have led to
an underestimate of the true mortality in the HIV-infected sub-
group whilst late detection and delayed management of AEs could
have contributed to mortality given that severe AEs occurred on
average about 2 months after mild to moderate AEs. Only a
prospective study will be able to address this hypothesis. There
were few events in the group with severe AEs and thus CIs were
wide, and larger studies are needed to confirm our findings.
Finally, our findings are only generalisable to a resource-poor high
HIV prevalence setting like South Africa where there is a high rate
of prior MDR-TB.
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In conclusion, the frequency of AEs with XDR-TB treatment
regimens is high and often severe. Those with severe AEs have
poorer treatment-related outcomes. Early detection and monitor-
ing of AEs is thus crucial, and XDR-TB patients with AEs should
be closely monitored for the remainder of their therapy. Assays to
monitor serum levels of second line drugs and less toxic drugs are
urgently needed. These data inform on the management and
monitoring of patients being treated for XDR-TB, factors that
impact on patient compliance, and the provision of resources
within national TB programmes that seek to offer decentralised
and nurse-led care for patients with XDR-TB.
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